title: Digital health revolution: perfect storm or perfect opportunity for pharmaceutical R&D?
abstract: The convergence of technology and medicine has pushed healthcare to the brink of a major disruption that pharma has, until recently, been slow to recognize. Tech players have pioneered the emerging field of digital wellness and health, and pharma is ideally placed to use its expertise in drug development and embrace these technologies to create digital applications that address major medical needs. This review describes digital innovation from a pharma R&D perspective, outlining principal drivers, digital components, opportunities and challenges as well as a sustainable new business model predicated on empowered patients and achieving therapeutic outcomes.
authors.affiliation: Takeda Pharmaceutical Company Limited, Fujisawa 251-8555, Japan. Electronic address: nicholas.hird@takeda.com.
authors.forename: Nick
authors.initials: N
authors.lastname: Hird
authors.affiliation: The Systems Biology Institute, Tokyo 108-0071, Japan.
authors.forename: Samik
authors.initials: S
authors.lastname: Ghosh
authors.affiliation: The Systems Biology Institute, Tokyo 108-0071, Japan.
authors.forename: Hiroaki
authors.initials: H
authors.lastname: Kitano
mesh_terms: D035843:Biomedical Research; D020811:Biomedical Technology; D003201:Computers; D004345:Drug Industry; D009936:Organizational Innovation